序贯多递增剂量solnatide治疗中重度ARDS肺渗透性水肿的安全性与初步疗效:随机安慰剂对照双盲试验
本研究为随机、安慰剂对照、双盲IIB期临床试验方案,受试者为需机械通气的中重度ARDS患者,随机接受递增剂量solnatide或安慰剂,每日两次给药7天,随访21天。主要目的是评估安全性及可能的疗效终点,数据安全监查委员会在剂量递增前审查安全性数据。
要点
- 中重度ARDS机械通气患者随机接受递增剂量solnatide或安慰剂,每日两次共7天。
- 剂量递增前由数据安全监查委员会审查安全性数据。
- 主要评估安全性及可能的疗效终点,随访期21天。
核心结论
- 该IIB期试验旨在评估solnatide在中重度ARDS患者中的安全性及可能疗效终点,结果尚未报告。
研究设计与样本
- 随机、安慰剂对照、双盲干预研究,受试者为需机械通气的中重度ARDS患者。
- 患者随机分配至平行组,分别接受递增剂量solnatide或安慰剂。
- 干预每日两次、持续7天,随后随访21天。
- 剂量递增前由数据安全监查委员会审查既往患者安全性数据。
关键数值与推荐
- 干预为每日两次给药,共7天,随访21天。
- 剂量递增前需经数据安全监查委员会审查安全性数据。
临床怎么用
- 该方案强调对昏迷或深度镇静患者需特别谨慎获取知情同意。
- 筛查及干预期数据采集量大,纳入时间窗短,需充分准备以保证数据可靠性。
局限性
- 本文为试验方案,尚未报告安全性或疗效结果。
- 纳入患者病情重且需机械通气,筛查与干预期数据量大而纳入时间窗短。
- 符合条件的患者纳入时多处于昏迷或深度镇静状态,知情同意需特别谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute respiratory distress syndrome (ARDS) is a complex clinical diagnosis with various possible etiologies. One common feature, however, is pulmonary permeability edema, which leads to an increased alveolar diffusion pathway and, subsequently, impaired oxygenation and decarboxylation. A novel inhaled peptide agent (AP301, solnatide) was shown to markedly reduce pulmonary edema in animal models of ARDS and to be safe to administer to healthy humans in a Phase I clinical trial. Here, we present the protocol for a Phase IIB clinical trial investigating the safety and possible future efficacy endpoints in ARDS patients. METHODS: This is a randomized, placebo-controlled, double-blind intervention study. Patients with moderate to severe ARDS in need of mechanical ventilation will be randomized to parallel groups receiving escalating doses of solnatide or placebo, respectively. Before advancing to a higher dose, a data safety monitoring board will investigate the data from previous patients for any indication of patient safety violations. The intervention (application of the investigational drug) takes places twice daily over the course of 7 days, ensued by a follow-up period of another 21 days. DISCUSSION: The patients to be included in this trial will be severely sick and in need of mechanical ventilation. The amount of data to be collected upon screening and during the course of the intervention phase is substantial and the potential timeframe for inclusion of any given patient is short. However, when prepared properly, adherence to this protocol will make for the acquisition of reliable data. Particular diligence needs to be exercised with respect to informed consent, because eligible patients will most likely be comatose and/or deeply sedated at the time of inclusion. TRIAL REGISTRATION: This trial was prospectively registered with the EU Clinical trials register (clinicaltrialsregister.eu). EudraCT Number: 2017-003855-47 .
引用
- Schmid B, Kredel M, Ullrich R, et al. Safety and preliminary efficacy of sequential multiple ascending doses of solnatide to treat pulmonary permeability edema in patients with moderate-to-severe ARDS-a randomized, placebo-controlled, double-blind trial. Trials. 2021. PMID: 34544463. doi:10.1186/s13063-021-05588-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。